Markus Grompe

List of Publications by Year in Descending Order

241 papers	27,833 citations	80 h-index	164 g-index
258 ext. papers	31,109 ext. citations	12.8 avg, IF	6.81 L-index

#	Paper	IF	Citations
241	Metformin for Treatment of Cytopenias in Children and Young Adults with Fanconi Anemia. *Blood*, **2021**, 138, 1102-1102	2.2	1
240	Generation of functional ciliated cholangiocytes from human pluripotent stem cells. *Nature Communications*, **2021**, 12, 6504	17.4	3
239	Cancer stem cells: advances in biology and clinical translation-a Keystone Symposia report. *Annals of the New York Academy of Sciences*, **2021**,	6.5	1
238	Therapeutic liver repopulation by transient acetaminophen selection of gene-modified hepatocytes. *Science Translational Medicine*, **2021**, 13,	17.5	2
237	Induced Liver Regeneration Enhances CRISPR/Cas9-Mediated Gene Repair in Tyrosinemia Type 1. *Human Gene Therapy*, **2021**, 32, 294-301	4.8	4
236	MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia. *Cell Stem Cell*, **2021**, 28, 33-47.e8	18	10
235	Inhibition of TGF1 and TGF3 promotes hematopoiesis in Fanconi anemia. *Experimental Hematology*, **2021**, 93, 70-84.e4	3.1	3
234	Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. *Molecular Therapy*, **2021**, 29, 680-690	11.7	11
233	Proliferative polyploid cells give rise to tumors via ploidy reduction. *Nature Communications*, **2021**, 12, 646	17.4	19
232	Dynamic Transcriptional and Epigenetic Changes Drive Cellular Plasticity in the Liver. *Hepatology*, **2021**, 74, 444-457	11.2	4
231	AAV integration in human hepatocytes. *Molecular Therapy*, **2021**, 29, 2898-2909	11.7	7
230	In vitro expansion of cirrhosis derived liver epithelial cells with defined small molecules. *Stem Cell Research*, **2021**, 56, 102523	1.6	0
229	Liver Repopulation by Cell Transplantation and the Role of Stem Cells in Liver Biology **2020**, 550-565		1
228	Efficient editing of OTC-deficient patient-derived primary human hepatocytes. *JHEP Reports*, **2020**, 2, 100065	10.3	8
227	AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 234-245	6.4	26
226	In Vivo Lineage Tracing of Polyploid Hepatocytes Reveals Extensive Proliferation during Liver Regeneration. *Cell Stem Cell*, **2020**, 26, 34-47.e3	18	60
225	Insights From Liver-Humanized Mice on Cholesterol Lipoprotein Metabolism and LXR-Agonist Pharmacodynamics in Humans. *Hepatology*, **2020**, 72, 656-670	11.2	6

224	Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. *Gastroenterology*, **2019**, 157, 552-568	13.3	39
223	Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. *JCI Insight* , **2019**, 4,	9.9	32
222	Replication Stress Response and CDKN1A Engagement Constrain Fetal Hematopoietic Stem Cell Pool Size in Fanconi Anemia. *Blood*, **2019**, 134, 107-107	2.2	
221	Diabetes relief in mice by glucose-sensing insulin-secreting human □cells. *Nature*, **2019**, 567, 43-48	50.4	104
220	Loss of Oxidation Resistance 1, OXR1, Is Associated with an Autosomal-Recessive Neurological Disease with Cerebellar Atrophy and Lysosomal Dysfunction. *American Journal of Human Genetics*, **2019**, 105, 1237-1253	11	17
219	Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model. *Pediatric Blood and Cancer*, **2019**, 66, e27460	3	3
218	Long-Term Correction of Diabetes in Mice by In□Vivo Reprogramming of Pancreatic Ducts. *Molecular Therapy*, **2018**, 26, 1327-1342	11.7	18
217	Bioengineered AAV Capsids with Combined High Human Liver Transduction In□Vivo and Unique Humoral Seroreactivity. *Molecular Therapy*, **2018**, 26, 289-303	11.7	97
216	Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA. *JCI Insight*, **2018**, 3,	9.9	49
215	Inflammatory Cytokine TNF□Promotes the Long-Term Expansion of Primary Hepatocytes in 3D Culture. *Cell*, **2018**, 175, 1607-1619.e15	56.2	118
214	Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. *Nature Communications*, **2018**, 9, 5068	17.4	281
213	A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia. *Cell Stem Cell*, **2017**, 20, 478-489.e5	18	75
212	Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. *Genetics in Medicine*, **2017**, 19,	8.1	99
211	Glycoprotein 2 is a specific cell surface marker of human pancreatic progenitors. *Nature Communications*, **2017**, 8, 331	17.4	67
210	Fah Knockout Animals as Models for Therapeutic Liver Repopulation. *Advances in Experimental Medicine and Biology*, **2017**, 959, 215-230	3.6	20
209	Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. *Nature Communications*, **2017**, 8, 1323	17.4	38
208	Adult Mouse Liver Contains Two Distinct Populations of Cholangiocytes. *Stem Cell Reports*, **2017**, 9, 478-489	4	47
207	Successful Engraftment of Human Hepatocytes in uPA-SCID and FRG KO Mice. *Methods in Molecular Biology*, **2017**, 1506, 117-130	1.4	13

206	Chronic Phenotype Characterization of a Large-Animal Model of Hereditary Tyrosinemia Type 1. *American Journal of Pathology*, **2017**, 187, 33-41	5.8	13
205	Reprogramming human gallbladder cells into insulin-producing like cells. *PLoS ONE*, **2017**, 12, e0181812	3.7	18
204	Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma. *Human Mutation*, **2016**, 37, 1097-105	4.7	17
203	Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. *Science Translational Medicine*, **2016**, 8, 349ra99	17.5	41
202	A universal system to select gene-modified hepatocytes in vivo. *Science Translational Medicine*, **2016**, 8, 342ra79	17.5	31
201	Human islets contain four distinct subtypes of cells. *Nature Communications*, **2016**, 7, 11756	17.4	211
200	TGF- Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. *Cell Stem Cell*, **2016**, 18, 668-81	18	89
199	Stem cells versus plasticity in liver and pancreas regeneration. *Nature Cell Biology*, **2016**, 18, 238-45	23.4	116
198	Identification of tissue-specific cell death using methylation patterns of circulating DNA. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E1826-34	11.5	350
197	Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. *Blood*, **2016**, 128, 2774-2784	2.2	39
196	Efficient generation of pancreatic like cells from the mouse gallbladder. *Stem Cell Research*, **2016**, 17, 587-596	1.6	11
195	Age-Dependent Pancreatic Gene Regulation Reveals Mechanisms Governing Human Cell Function. *Cell Metabolism*, **2016**, 23, 909-20	24.6	153
194	Single-Cell Mass Cytometry Analysis of the Human Endocrine Pancreas. *Cell Metabolism*, **2016**, 24, 616-626	24.6	104
193	Directed differentiation of cholangiocytes from human pluripotent stem cells. *Nature Biotechnology*, **2015**, 33, 853-61	44.5	193
192	Novel surface markers directed against adult human gallbladder. *Stem Cell Research*, **2015**, 15, 172-81	1.6	5
191	The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice. *Stem Cell Research*, **2015**, 15, 130-40	1.6	15
190	Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers. *Gastroenterology*, **2015**, 149, 728-40.e15	13.3	75
189	Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling. *Stem Cell Reports*, **2015**, 4, 90-102	8	20

188	Pharmacologic inhibition of L-tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU). *Journal of Inherited Metabolic Disease*, **2014**, 37, 735-43	5.4	29
187	Evaluation of resveratrol and N-acetylcysteine for cancer chemoprevention in a Fanconi anemia murine model. *Pediatric Blood and Cancer*, **2014**, 61, 740-2	3	10
186	Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. *Nature*, **2014**, 506, 382-6	50.4	279
185	Extensive double humanization of both liver and hematopoiesis in FRGN mice. *Stem Cell Research*, **2014**, 13, 404-12	1.6	105
184	Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. *Cell Stem Cell*, **2014**, 15, 605-18	18	338
183	The organoid-initiating cells in mouse pancreas and liver are phenotypically and functionally similar. *Stem Cell Research*, **2014**, 13, 275-83	1.6	59
182	Liver stem cells, where art thou?. *Cell Stem Cell*, **2014**, 15, 257-258	18	63
181	Clonal tracing of Sox9+ liver progenitors in mouse oval cell injury. *Hepatology*, **2014**, 60, 278-89	11.2	165
180	Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease. *Stem Cell Research*, **2014**, 13, 144-53	1.6	44
179	Adult Liver Stem Cells **2014**, 309-327		
178	Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. *Nature Biotechnology*, **2014**, 32, 551-3	44.5	694
177	Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia. *Cancer Cytopathology*, **2013**, 121, 37-46	3.9	2
176	Response to "Can 'humanized' mice improve drug development in the 21st century?". *Trends in Pharmacological Sciences*, **2013**, 34, 425	13.2	5
175	Generation of islet-like cells from mouse gall bladder by direct ex vivo reprogramming. *Stem Cell Research*, **2013**, 11, 503-15	1.6	33
174	Assessing the potential of induced liver regeneration. *Nature Medicine*, **2013**, 19, 1096-7	50.5	9
173	Anthracyclines induce DNA damage response-mediated protection against severe sepsis. *Immunity*, **2013**, 39, 874-84	32.3	105
172	New potential cell source for hepatocyte transplantation: discarded livers from metabolic disease liver transplants. *Stem Cell Research*, **2013**, 11, 563-73	1.6	42
171	Mice with human livers. *Gastroenterology*, **2013**, 145, 1209-14	13.3	92

170	Fancd2 and p21 function independently in maintaining the size of hematopoietic stem and progenitor cell pool in mice. *Stem Cell Research*, **2013**, 11, 687-92	1.6	9
169	p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver. *Hepatology*, **2013**, 57, 2004-13	11.2	66
168	In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. *Nature*, **2013** , 494, 247-50	50.4	936
167	Adult Liver Stem Cells **2013**, 873-887		
166	A therapy for liver failure found in the JNK yard. *Cell*, **2013**, 153, 283-4	56.2	5
165	Epigenomic plasticity enables human pancreatic to cell reprogramming. *Journal of Clinical Investigation*, **2013**, 123, 1275-84	15.9	294
164	Mice with chimeric livers are an improved model for human lipoprotein metabolism. *PLoS ONE*, **2013**, 8, e78550	3.7	32
163	Frequent aneuploidy among normal human hepatocytes. *Gastroenterology*, **2012**, 142, 25-8	13.3	151
162	AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo. *Human Gene Therapy*, **2012**, 23, 658-65	4.8	23
161	Tissue stem cells: new tools and functional diversity. *Cell Stem Cell*, **2012**, 10, 685-689	18	45
160	Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. *Cell Stem Cell*, **2012**, 11, 36-49	18	195
159	The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma. *Human Pathology*, **2012**, 43, 1583-9	3.7	14
158	AAV vectors containing rDNA homology display increased chromosomal integration and transgene persistence. *Molecular Therapy*, **2012**, 20, 1902-11	11.7	28
157	In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice. *Molecular Therapy*, **2012**, 20, 1981-7	11.7	12
156	Ribosomal DNA integrating rAAV-rDNA vectors allow for stable transgene expression. *Molecular Therapy*, **2012**, 20, 1912-23	11.7	24
155	Intra-hematopoietic cell fusion as a source of somatic variation in the hematopoietic system. *Journal of Cell Science*, **2012**, 125, 2837-43	5.3	19
154	Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. *Journal of Clinical Investigation*, **2012**, 122, 3618-28	15.9	149
153	Aneuploidy as a mechanism for stress-induced liver adaptation. *Journal of Clinical Investigation*, **2012**, 122, 3307-15	15.9	121

152	Intra-hematopoietic cell fusion as a source of somatic variation in the hematopoietic system. *Development (Cambridge)*, **2012**, 139, e1707-e1707	6.6	
151	Isolation of mouse pancreatic alpha, beta, duct and acinar populations with cell surface markers. *Molecular and Cellular Endocrinology*, **2011**, 339, 144-50	4.4	35
150	Transcriptomes of the major human pancreatic cell types. *Diabetologia*, **2011**, 54, 2832-44	10.3	156
149	Fanconi anemia-like presentation in an infant with constitutional deletion of 21q including the RUNX1 gene. *American Journal of Medical Genetics, Part A*, **2011**, 155A, 1673-9	2.5	16
148	Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer. *Hepatology*, **2011**, 54, 1351-9	11.2	59
147	Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. *Journal of Experimental Medicine*, **2011**, 208, 1963-76	16.6	153
146	Foxl1-Cre-marked adult hepatic progenitors have clonogenic and bilineage differentiation potential. *Genes and Development*, **2011**, 25, 1185-92	12.6	116
145	Prospective isolation of a bipotential clonogenic liver progenitor cell in adult mice. *Genes and Development*, **2011**, 25, 1193-203	12.6	191
144	Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. *Journal of Cell Biology*, **2011**, 194, i11-i11	7.3	
143	The ploidy conveyor of mature hepatocytes as a source of genetic variation. *Nature*, **2010**, 467, 707-10	50.4	354
142	Non-invasive stem cell therapy in a rat model for retinal degeneration and vascular pathology. *PLoS ONE*, **2010**, 5, e9200	3.7	97
141	Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. *Cancer Research*, **2010**, 70, 9959-68	10.1	69
140	Therapeutic liver reconstitution with murine cells isolated long after death. *Gastroenterology*, **2010**, 139, 1019-29	13.3	25
139	Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. *Methods in Molecular Biology*, **2010**, 640, 491-509	1.4	109
138	Chromosomal integration of adenoviral vector DNA in vivo. *Journal of Virology*, **2010**, 84, 9987-94	6.6	59
137	Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol. *Blood*, **2010**, 116, 5140-8	2.2	68
136	Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. *Hepatology*, **2010**, 51, 1200-8	11.2	97
135	Validation of Fanconi anemia complementation Group A assignment using molecular analysis. *Genetics in Medicine*, **2009**, 11, 183-92	8.1	11

134	Ploidy reductions in murine fusion-derived hepatocytes. *PLoS Genetics*, **2009**, 5, e1000385	6	82
133	Embryonic lethality after combined inactivation of Fancd2 and Mlh1 in mice. *Cancer Research*, **2009**, 69, 9431-8	10.1	8
132	Generation of monoclonal antibodies specific for cell surface molecules expressed on early mouse endoderm. *Stem Cells*, **2009**, 27, 2103-13	5.8	36
131	CDX2 in the formation of the trophectoderm lineage in primate embryos. *Developmental Biology*, **2009**, 335, 179-87	3.1	32
130	Stem cells and liver regeneration. *Gastroenterology*, **2009**, 137, 466-81	13.3	388
129	Adult Liver Stem Cells **2009**, 285-298		1
128	CXCR4 induction in hematopoietic progenitor cells from Fanca(-/-), -c(-/-), and -d2(-/-) mice. *Experimental Hematology*, **2008**, 36, 273-82	3.1	11
127	Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. *Cancer Cell*, **2008**, 14, 59-67	24.3	50
126	Isolation of major pancreatic cell types and long-term culture-initiating cells using novel human surface markers. *Stem Cell Research*, **2008**, 1, 183-94	1.6	78
125	ERCC1 is required for FANCD2 focus formation. *Molecular Genetics and Metabolism*, **2008**, 95, 66-73	3.7	15
124	Generation and regeneration of cells of the liver and pancreas. *Science*, **2008**, 322, 1490-4	33.3	468
123	Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice. *Cancer Research*, **2008**, 68, 1601-8	10.1	57
122	Bone Marrow-Derived Hepatocytes. *Novartis Foundation Symposium*, **2008**, 20-34		19
121	Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. *Hepatology*, **2008**, 48, 487-96	11.2	30
120	Surface markers for the murine oval cell response. *Hepatology*, **2008**, 48, 1282-91	11.2	78
119	Signaling networks in hepatic oval cell activation. *Stem Cell Research*, **2007**, 1, 90-102	1.6	42
118	Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. *Nature Biotechnology*, **2007**, 25, 903-10	44.5	599
117	Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate: kinetics, crystal structure and pharmacokinetics. *Biochemical Journal*, **2007**, 402, 251-60	3.8	13

116	The Fanconi family adds a fraternal twin. *Developmental Cell*, **2007**, 12, 661-2	10.2	30
115	Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. *American Journal of Human Genetics*, **2007**, 80, 895-910	11	92
114	Myeloid lineage progenitors give rise to vascular endothelium. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 13156-61	11.5	162
113	In vivo genetic selection of renal proximal tubules. *Molecular Therapy*, **2006**, 13, 49-58	11.7	51
112	Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 6321-5	11.5	219
111	Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases. *Gastroenterology*, **2006**, 130, 104-19	13.3	27
110	Natural gene therapy in monozygotic twins with Fanconi anemia. *Blood*, **2006**, 107, 3084-90	2.2	68
109	Principles of therapeutic liver repopulation. *Journal of Inherited Metabolic Disease*, **2006**, 29, 421-5	5.4	43
108	Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. *Journal of Clinical Investigation*, **2006**, 116, 3070-82	15.9	148
107	The origin of hepatocytes. *Gastroenterology*, **2005**, 128, 2158-60	13.3	17
106	Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. *Blood*, **2005**, 105, 1003-9	2.2	111
105	Liver repair by intra- and extrahepatic progenitors. *Stem Cell Reviews and Reports*, **2005**, 1, 61-4	6.4	32
104	Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. *Journal of Virology*, **2005**, 79, 3606-14	6.6	139
103	In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. *Molecular Therapy*, **2005**, 11, 399-408	11.7	110
102	Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria. *Molecular Therapy*, **2005**, 12, 337-44	11.7	39
101	Fancd2 functions in a double strand break repair pathway that is distinct from non-homologous end joining. *Human Molecular Genetics*, **2005**, 14, 3027-33	5.6	47
100	Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice. *Cancer Research*, **2005**, 65, 85-91	10.1	42
99	Bone marrow-derived hepatocytes. *Novartis Foundation Symposium*, **2005**, 265, 20-7; discussion 28-34, 92-7		7

98	Adult Liver Stem Cells **2004**, 483-495		
97	Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. *Molecular and Cellular Biology*, **2004**, 24, 123-34	4.8	200
96	Delineating the hepatocyte's hematopoietic fusion partner. *Cell Cycle*, **2004**, 3, 1489-91	4.7	16
95	Liver-directed adenoviral gene transfer in murine succinate semialdehyde dehydrogenase deficiency. *Molecular Therapy*, **2004**, 9, 527-39	11.7	16
94	Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1. *Kidney International*, **2004**, 66, 990-1000	9.9	5
93	Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. *Nature Medicine*, **2004**, 10, 744-8	50.5	359
92	Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. *Hepatology*, **2004**, 39, 433-43	11.2	53
91	Interstrand crosslink-induced radials form between non-homologous chromosomes, but are absent in sex chromosomes. *DNA Repair*, **2004**, 3, 535-42	4.3	25
90	Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. *Molecular Therapy*, **2003**, 7, 101-11	11.7	44
89	The role of bone marrow stem cells in liver regeneration. *Seminars in Liver Disease*, **2003**, 23, 363-72	7.3	77
88	Reply to Involvement of oxidative stress in Fanconi's anaemia: from phenotype to FA protein functions *Nature Reviews Cancer*, **2003**, 3, 78-78	31.3	
87	Embryonic versus adult stem cell pluripotency: in liver only fusion matters. *Journal of Assisted Reproduction and Genetics*, **2003**, 20, 393-4	3.4	7
86	Pharmacologic or genetic ablation of maleylacetoacetate isomerase increases levels of toxic tyrosine catabolites in rodents. *Biochemical Pharmacology*, **2003**, 66, 2029-38	6	26
85	Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. *Human Mutation*, **2003**, 22, 442-50	4.7	98
84	Murine succinate semialdehyde dehydrogenase deficiency. *Annals of Neurology*, **2003**, 54 Suppl 6, S81-90	9.4	43
83	Cell fusion is the principal source of bone-marrow-derived hepatocytes. *Nature*, **2003**, 422, 897-901	50.4	1370
82	AAV serotype 2 vectors preferentially integrate into active genes in mice. *Nature Genetics*, **2003**, 34, 297-302	36.3	303
81	The Fanconi anaemia/BRCA pathway. *Nature Reviews Cancer*, **2003**, 3, 23-34	31.3	680

80	Pancreatic-hepatic switches in vivo. *Mechanisms of Development*, **2003**, 120, 99-106	1.7	44
79	The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. *Cell*, **2003**, 113, 445-56	56.2	281
78	Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. *Genes and Development*, **2003**, 17, 2021-35	12.6	200
77	The origin and liver repopulating capacity of murine oval cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100 Suppl 1, 11881-8	11.5	358
76	Adult versus embryonic stem cells: it's still a tie. *Molecular Therapy*, **2002**, 6, 303-5	11.7	24
75	Fanconi anemia group A and C double-mutant mice: functional evidence for a multi-protein Fanconi anemia complex. *Experimental Hematology*, **2002**, 30, 679-88	3.1	53
74	In vivo administration of interferon gamma does not cause marrow aplasia in mice with a targeted disruption of FANCC. *Experimental Hematology*, **2002**, 30, 1257-62	3.1	5
73	SV40 large T-antigen disturbs the formation of nuclear DNA-repair foci containing MRE11. *Oncogene*, **2002**, 21, 4873-8	9.2	55
72	Transition of stem cells to therapeutically functional tissue-specific cells. *Annals of the New York Academy of Sciences*, **2002**, 961, 305-6	6.5	4
71	In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. *Molecular Therapy*, **2002**, 6, 759-69	11.7	124
70	Biallelic inactivation of BRCA2 in Fanconi anemia. *Science*, **2002**, 297, 606-9	33.3	947
69	Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia. *Carcinogenesis*, **2002**, 23, 1121-6	4.6	69
68	Gene therapy and pediatric liver disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2002**, 35 Suppl 1, S51-4	2.8	4
67	BRCA1 interacts directly with the Fanconi anemia protein FANCA. *Human Molecular Genetics*, **2002**, 11, 2591-7	5.6	78
66	Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 302, 180-7	4.7	73
65	Maleylacetoacetate isomerase (MAAI/GSTZ)-deficient mice reveal a glutathione-dependent nonenzymatic bypass in tyrosine catabolism. *Molecular and Cellular Biology*, **2002**, 22, 4943-51	4.8	72
64	S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. *Blood*, **2002**, 100, 2414-20	2.2	395
63	Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. *Blood*, **2002**, 100, 2732-6	2.2	75

62	Kinetics of liver repopulation after bone marrow transplantation. *American Journal of Pathology*, **2002**, 161, 565-74	5.8	206
61	Mutations in PHF6 are associated with B□jeson-Forssman-Lehmann syndrome. *Nature Genetics*, **2002**, 32, 661-5	36.3	168
60	Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. 1991. *Journal of Hepatology*, **2002**, 37, 422-4	13.4	2
59	Liver repopulation for the treatment of metabolic diseases. *Journal of Inherited Metabolic Disease*, **2001**, 24, 231-44	5.4	41
58	Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9. *Experimental Hematology*, **2001**, 29, 842-9	3.1	20
57	Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells. *Experimental Hematology*, **2001**, 29, 1448-55	3.1	33
56	Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in Fanconi anemia group C. *Molecular Therapy*, **2001**, 3, 14-23	11.7	35
55	Fanconi anemia and DNA repair. *Human Molecular Genetics*, **2001**, 10, 2253-9	5.6	115
54	Mechanistic inferences from the crystal structure of fumarylacetoacetate hydrolase with a bound phosphorus-based inhibitor. *Journal of Biological Chemistry*, **2001**, 276, 15284-91	5.4	48
53	The pathophysiology and treatment of hereditary tyrosinemia type 1. *Seminars in Liver Disease*, **2001**, 21, 563-71	7.3	121
52	The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. *Molecular Genetics and Metabolism*, **2001**, 74, 403-12	3.7	61
51	Liver repopulation and correction of metabolic liver disease by transplanted adult mouse pancreatic cells. *American Journal of Pathology*, **2001**, 158, 571-9	5.8	107
50	Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. *Nature Genetics*, **2001**, 29, 212-6	36.3	133
49	Positional cloning of a novel Fanconi anemia gene, FANCD2. *Molecular Cell*, **2001**, 7, 241-8	17.6	335
48	Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. *Molecular Cell*, **2001**, 7, 249-62	17.6	1018
47	Chemical cleavage of heteroduplex DNA to identify mutations. *Current Protocols in Human Genetics*, **2001**, Chapter 7, Unit 7.6	3.2	
46	Loss of p27Kip1 enhances the transplantation efficiency of hepatocytes transferred into diseased livers. *Journal of Clinical Investigation*, **2001**, 108, 383-390	15.9	42
45	Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. *Nature Medicine*, **2000**, 6, 1229-34	50.5	2012

44	Phenotypic correction of Fanconi anemia group C knockout mice. *Blood*, **2000**, 95, 700-704	2.2	51
43	DNA replication is required To elicit cellular responses to psoralen-induced DNA interstrand cross-links. *Molecular and Cellular Biology*, **2000**, 20, 8283-9	4.8	174
42	Localization of the Fanconi anemia complementation group D gene to a 200-kb region on chromosome 3p25.3. *American Journal of Human Genetics*, **2000**, 66, 1540-51	11	29
41	Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. *Science*, **2000**, 288, 2045-7	33.3	316
40	DNA Replication Is Required To Elicit Cellular Responses to Psoralen-Induced DNA Interstrand Cross-Links. *Molecular and Cellular Biology*, **2000**, 20, 8283-8289	4.8	5
39	In Vivo Selection of Wild-Type Hematopoietic Stem Cells in a Murine Model of Fanconi Anemia. *Blood*, **1999**, 94, 2151-2158	2.2	47
38	Principles of therapeutic liver repopulation. *Seminars in Liver Disease*, **1999**, 19, 7-14	7.3	78
37	Embryonic stem cells can be used to construct hybrid cell lines containing a single, selectable murine chromosome. *Mammalian Genome*, **1999**, 10, 381-4	3.2	1
36	Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice. *Journal of Cellular Physiology*, **1999**, 179, 79-86	7	51
35	Identification of the mutation in the alkaptonuria mouse model. Mutations in brief no. 216. Online. *Human Mutation*, **1999**, 13, 171	4.7	48
34	The repopulation potential of hepatocyte populations differing in size and prior mitotic expansion. *American Journal of Pathology*, **1999**, 155, 2135-43	5.8	158
33	Gene structure, chromosomal location, and expression pattern of maleylacetoacetate isomerase. *Genomics*, **1999**, 58, 263-9	4.3	39
32	Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I. *Human Gene Therapy*, **1998**, 9, 295-304	4.8	59
31	Subtyping Analysis of Fanconi Anemia by Immunoblotting and Retroviral Gene Transfer. *Molecular Medicine*, **1998**, 4, 468-479	6.2	49
30	DNA Cross-Linker□Induced G2/M Arrest in Group C Fanconi Anemia Lymphoblasts Reflects Normal Checkpoint Function. *Blood*, **1998**, 91, 275-287	2.2	59
29	DNA Cross-Linker□Induced G2/M Arrest in Group C Fanconi Anemia Lymphoblasts Reflects Normal Checkpoint Function. *Blood*, **1998**, 91, 275-287	2.2	1
28	Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. *Human Gene Therapy*, **1997**, 8, 513-21	4.8	58
27	Molecular Biology of Fanconi Anemia: Implications for Diagnosis and Therapy. *Blood*, **1997**, 90, 1725-1736	6.2	174

26	Inactivation of the Fanconi Anemia Group C Gene Augments Interferon-Induced Apoptotic Responses in Hematopoietic Cells. *Blood*, **1997**, 90, 974-985	2.2	152
25	Inactivation of the Fanconi Anemia Group C Gene Augments Interferon-Induced Apoptotic Responses in Hematopoietic Cells. *Blood*, **1997**, 90, 974-985	2.2	9
24	[1]Chemical mismatch cleavage. *Methods in Molecular Genetics*, **1996**, 3-13		
23	Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I. *Human Mutation*, **1996**, 7, 367-9	4.7	8
22	Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. *Nature Genetics*, **1996**, 12, 266-73	36.3	475
21	Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. *Nature Genetics*, **1995**, 10, 453-60	36.3	261
20	Microcell mediated chromosome transfer maps the Fanconi anaemia group D gene to chromosome 3p. *Nature Genetics*, **1995**, 11, 341-3	36.3	118
19	Cloning and characterization of a human cDNA (INPPL1) sharing homology with inositol polyphosphate phosphatases. *Genomics*, **1995**, 29, 285-7	4.3	40
18	Rapid nonradioactive assay for the detection of the common French Canadian tyrosinemia type I mutation. *Human Mutation*, **1995**, 5, 105	4.7	10
17	A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. *New England Journal of Medicine*, **1994**, 331, 353-7	59.2	114
16	Fanconi anemia cells have a normal gene structure for topoisomerase I. *Human Genetics*, **1994**, 93, 583-6	6.3	5
15	The Ashkenazi Jewish Fanconi anemia mutation: incidence among patients and carrier frequency in the at-risk population. *Human Mutation*, **1994**, 3, 339-41	4.7	35
14	Microphthalmia with linear skin defects (MLS) syndrome: clinical, cytogenetic, and molecular characterization. *American Journal of Medical Genetics Part A*, **1994**, 49, 229-34		92
13	Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I. *Human Mutation*, **1993**, 2, 85-93	4.7	45
12	A common mutation in the FACC gene causes Fanconi anaemia in Ashkenazi Jews. *Nature Genetics*, **1993**, 4, 202-5	36.3	141
11	The rapid detection of unknown mutations in nucleic acids. *Nature Genetics*, **1993**, 5, 111-7	36.3	297
10	Retroviral-mediated gene transfer of human ornithine transcarbamylase into primary hepatocytes of spf and spf-ash mice. *Human Gene Therapy*, **1992**, 3, 35-44	4.8	51
9	The sulfatase gene family: cross-species PCR cloning using the MOPAC technique. *Genomics*, **1992**, 12, 755-60	4.3	15

8	Point mutations and polymorphisms in the human dystrophin gene identified in genomic DNA sequences amplified by multiplex PCR. *Human Genetics*, **1992**, 89, 253-8	6.3	45
7	Nucleotide sequence of a cDNA encoding murine fumarylacetoacetate hydrolase. *Biochemical Medicine and Metabolic Biology*, **1992**, 48, 26-31		13
6	A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. *Nature*, **1991**, 349, 38-44	50.4	1164
5	Characterization of a murine gene expressed from the inactive X chromosome. *Nature*, **1991**, 351, 325-9	50.4	471
4	Molecular detection and correction of ornithine transcarbamylase deficiency. *Trends in Genetics*, **1990**, 6, 335-9	8.5	13
3	Scanning detection of mutations in human ornithine transcarbamoylase by chemical mismatch cleavage. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 5888-92	11.5	116
2	Liver Repopulation by Cell Transplantation and the Role of Stem Cells577-595		1
1	Specific detection of cell-free DNA derived from intestinal epithelial cells using methylation patterns		2